https://rheumatologydigest.org/tags/ralinepag/Recent content in Ralinepag on Rheumatology DigestHugoen-usFri, 07 Aug 2026 20:00:00 +0530https://rheumatologydigest.org/posts/advance-outcomes-ralinepag-pah/Fri, 07 Aug 2026 20:00:00 +0530https://rheumatologydigest.org/posts/advance-outcomes-ralinepag-pah/ADVANCE OUTCOMES is a phase 3 trial of once-daily oral ralinepag, a prostacyclin IP receptor agonist, added to background therapy in pulmonary arterial hypertension. It cut first clinical worsening by 55% (HR 0.45) — but the effect was carried entirely by softer composite components, with death and hospitalisation unchanged, and 19% discontinued for adverse events. CTD-PAH made up 29% of the cohort as a prespecified stratum.